Wall Street analysts forecast that Prothena Co. PLC (NASDAQ:PRTA) will post $260,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Prothena’s earnings. The lowest sales estimate is $230,000.00 and the highest is $300,000.00. Prothena posted sales of $230,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 13%. The company is expected to issue its next quarterly earnings report on Wednesday, February 13th.

On average, analysts expect that Prothena will report full year sales of $980,000.00 for the current year, with estimates ranging from $960,000.00 to $1.00 million. For the next fiscal year, analysts expect that the business will report sales of $25.95 million, with estimates ranging from $900,000.00 to $51.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Prothena.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.43. The business had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.26 million. Prothena had a negative return on equity of 43.17% and a negative net margin of 18,276.97%.

PRTA has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Friday, August 10th. Oppenheimer reiterated a “hold” rating on shares of Prothena in a research note on Sunday. BidaskClub upgraded shares of Prothena from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. ValuEngine upgraded shares of Prothena from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 target price on shares of Prothena in a research note on Wednesday, August 8th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $36.67.

Shares of PRTA opened at $11.43 on Wednesday. The firm has a market cap of $494.71 million, a price-to-earnings ratio of -2.81 and a beta of 2.63. Prothena has a 1-year low of $10.43 and a 1-year high of $57.00.

A number of institutional investors and hedge funds have recently made changes to their positions in PRTA. Dimensional Fund Advisors LP purchased a new stake in shares of Prothena in the 2nd quarter worth $7,801,000. Platinum Investment Management Ltd. increased its stake in shares of Prothena by 72.9% in the 2nd quarter. Platinum Investment Management Ltd. now owns 135,200 shares of the biotechnology company’s stock worth $1,971,000 after purchasing an additional 57,000 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Prothena by 16.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 204,787 shares of the biotechnology company’s stock worth $2,986,000 after purchasing an additional 29,533 shares in the last quarter. Scopia Capital Management LP purchased a new stake in shares of Prothena in the 2nd quarter worth $51,189,000. Finally, Oppenheimer & Co. Inc. increased its stake in shares of Prothena by 47.7% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 11,455 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 3,700 shares in the last quarter.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Featured Article: Technical Analysis

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.